Trastuzumab rezetecan for HER2-positive advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer that is advanced, cannot be removed with surgery, or has spread to other parts of your body.
- You have already tried at least one type of cancer treatment for your advanced or metastatic cancer, or there is no good standard treatment option left.
- Your tumor tests positive for a protein called HER2 (levels of 1+, 2+, or 3+).
- You are able to do your daily activities with little to no assistance (ECOG 0 or 1).
- You have at least one measurable tumor on a scan, and your major organs (like liver, kidneys, and blood counts) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial tests a new sequence of targeted therapies for advanced HER2-positive breast cancer. It aims to see if giving these drugs in a specific order can shrink tumors and delay progression better than current approaches.
Hear when a new Locally Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.